Barinthus Bio Said Initial Data From The Combination Of Imdusiran And VTP-300 Show Meaningful Reductions Of HBsAg Levels That Were Maintained Well Below Baseline.
Portfolio Pulse from Charles Gross
Barinthus Biotherapeutics (BRNS) announced data from two HBV clinical trials at The American Association for the Study of Liver Diseases. The data includes results from a Phase 2b trial of VTP-300 combined with a low-dose anti-PD-1 antibody and standard-of-care (SoC) nucleos(t)ide analogue (NUC) therapy. Additionally, interim data from a Phase 2a trial combining Arbutus Biopharma Corporation’s (ABUS) RNAi therapeutic candidate, imdusiran, with Barinthus Bio’s VTP-300 and SoC NUC therapy was presented. The initial data shows meaningful reductions of HBsAg levels.
November 09, 2023 | 9:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arbutus Biopharma's RNAi therapeutic candidate, imdusiran, was used in combination with Barinthus Bio's VTP-300 in a clinical trial. The initial data shows meaningful reductions of HBsAg levels.
The positive clinical trial data involving Arbutus Biopharma's imdusiran could potentially increase investor interest in the company and lead to a rise in its stock price in the short term. The data shows that imdusiran, when used in combination with Barinthus Bio's VTP-300, is effective in reducing HBsAg levels.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Barinthus Bio announced promising data from two clinical trials involving its product VTP-300. The data shows meaningful reductions of HBsAg levels.
The announcement of positive clinical trial data is typically a positive catalyst for biotech companies. The data shows that VTP-300, a product of Barinthus Bio, is effective in reducing HBsAg levels, which could potentially lead to increased investor interest and a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100